Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease

Table 3 Analysis of prognostic factors in patients with polymyositis/dermatomyositis-related interstitial lung disease using the Cox proportional hazard model

Variables	Unadjusted HR	95% CI	P	Age-adjusted and gender-adjusted HR	95% CI	P
Age (per 1 year increase)	1.01	0.96–1.07	0.62	−	−	−
Male	1.93	0.61–6.09	0.26	−	−	−
Current or former smoker	2.27	0.71–7.23	0.17	1.96	0.47–8.24	0.36
CADM	0.37	0.10–1.38	0.14	0.41	0.11–1.60	0.12
Fever	4.29	1.27–14.50	0.02	4.68	1.36–16.10	0.01
Cough	0.65	0.20–2.16	0.48	0.76	0.22–2.67	0.67
Dyspnea	2.30	0.69–7.64	0.18	2.65	0.78–9.03	0.12
Muscle pain or weakness	2.69	0.73–9.97	0.14	2.44	0.63–9.48	0.20
Rash typical for DM	0.40	0.09–1.85	0.24	0.47	0.10–2.27	0.35
Raynaud’s phenomenon	2.99	0.81–11.13	0.10	3.03	0.72–12.84	0.13
Arthralgia	1.54	0.49–4.90	0.46	1.39	0.42–4.59	0.59
CK (per 10 IU/mL increase)	1.00	0.995–1.01	0.97	1.00	0.994–1.006	0.96
CRP (per 1 mg/dL increase)	1.13	0.91–1.41	0.27	1.13	0.91–1.41	0.27
KL-6 (per 100 U/mL increase)	1.06	0.998–1.12	0.06	1.05	0.995–1.12	0.07
Ferritin (per 100 ng/mL increase)	1.02	1.01–1.04	0.01	1.03	1.01–1.05	0.01
Soluble CD163 (per 100 ng/mL increase)	1.22	1.09–1.36	0.001	1.27	1.11–1.45	<0.001
PaO₂ on room air (per 10 Torr increase)	0.48	0.30–0.76	0.002	0.48	0.28–0.81	0.01
Anti-MDA5-positive	2.60	0.81–8.32	0.11	3.11	0.90–10.74	0.07
Percent predicted FVC (per 10% increase)	0.73	0.61–0.88	0.001	0.65	0.50–0.83	0.001

ARS aminoacyl-tRNA synthetase, CADM clinically amyopathic dermatomyositis, CI confidence interval, CK creatine kinase, CRP C-reactive protein, DM dermatomyositis, FVC forced vital capacity, HR hazard ratio, KL-6 Krebs von den Lungen-6, MDA5 melanoma differentiation-associated gene 5

ISSN: 1478-6362